Latest Medicinal Cannabis News

Page 1 of 12
Cann Group says its balance-sheet repair and cost cuts have created room for growth, with September-quarter revenue and exports jumping. But the medicinal cannabis producer remains loss-making on a normalised basis and is now under pressure to turn improving sales into consistently positive cash flow.
Ada Torres
Ada Torres
18 Nov 2026
LGP Cannatrek generated A$4.4 million in net operating cash flow on unaudited quarterly revenue of A$26.0 million, providing the first clean look at the merged group’s operations. Cost synergies, Danish production upgrades and UK expansion are advancing, while a pending TGA penalty remains an unresolved risk.
Ada Torres
Ada Torres
30 Oct 2026
Epsilon Healthcare delivered record September-quarter customer receipts of A$3.9 million, while nine-month revenue reached A$11.5 million. The growth story is strengthening, but cash fell to A$997,000 and quarterly operating cash flow remained negative.
Ada Torres
Ada Torres
30 Oct 2026
Cann Group’s September quarter delivered a sharp increase in revenue and exports as its Mildura GMP facility gained traction in Europe. But with just $49,000 in cash, $626,000 of undrawn debt capacity and an estimated 0.9 quarters of funding, the recovery still depends on collections and further financing.
Ada Torres
Ada Torres
30 Oct 2026
Rua Bioscience has raised approximately NZ$1.0 million through its rights offer, well short of the NZ$2.8 million sought. The medicinal cannabis company says it still needs more working capital to fund inventory for its UK expansion.
Ada Torres
Ada Torres
20 Oct 2026
ECS Botanics has delivered a fifth consecutive quarter of positive operating cash flow, while branded sales and international expansion continue to reshape the business. The next test is whether planned UK and Polish launches can convert into recurring revenue.
Ada Torres
Ada Torres
19 Oct 2026
Vitura Health grew FY2026 revenue 6% to $131.2 million, but a sharp margin squeeze pushed the ASX-listed digital health company into a $4.4 million statutory loss. With ANZ debt classified as current and a potential $6 million FY2027 revenue hit from changed Bupa referrals, the promised turnaround faces a demanding test.
Ada Torres
Ada Torres
16 Oct 2026
Vitura Health has opened FY2027 with a sharp improvement in EBITDA and lower operating costs, while revenue growth continued across its digital health businesses. The figures are unaudited, and the company still needs to prove that the improvement can survive the wind-down of Bupa-related telehealth volumes.
Ada Torres
Ada Torres
13 Oct 2026
ECS Botanics is taking six Australian-grown medicinal cannabis flower products into the UK through Curaleaf Laboratories, with initial supply targeted for November. The two-year deal offers access to UK sell-through but no guaranteed volumes, revenue or minimum purchases.
Victor Sage
Victor Sage
7 Oct 2026
Cann Group’s FY2026 profit was transformed by a one-off A$55.7 million debt-forgiveness gain, while a leaner cost base and new export sales offered more durable progress. The company remains loss-making on a normalised basis and dependent on lender waivers and a future refinancing.
Victor Sage
Victor Sage
30 Sept 2026
Rua Bioscience delivered a sharp rise in customer revenue and secured a UK agreement expected to generate NZ$10 million over two years. But PwC disclaimed an audit opinion, warning the company may not have enough cash without another capital raise.
Ada Torres
Ada Torres
22 Sept 2026
BLS Pharmaceuticals (ASX: BLS) reported a standout FY26 with revenue surging 161% to $74.2 million and net profit more than tripling to $15.4 million, driven by expanded manufacturing and major international contracts including a $50 million German supply deal.
Victor Sage
Victor Sage
31 Aug 2026

Browse the archive

Full archive